Randomized, Double-blind, Placebo-controlled, Escalating Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered BAY1161116 in Healthy Postmenopausal Women Including Food-effect and Drug-drug-interaction With Itraconazole
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Nov 2017
At a glance
- Drugs BAY 1161116 (Primary) ; Itraconazole
- Indications Polycystic ovary syndrome
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer
- 21 Nov 2017 Planned End Date changed from 29 Nov 2017 to 18 Dec 2017.
- 22 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 16 May 2017 Status changed from not yet recruiting to recruiting.